This article is more than 5 years old. Information may no longer be current.
InDex announces US patent for UC drug candidate cobitolimod
Click Here to Manage Email Alerts
InDex Pharmaceuticals has received a new method of use patent in the U.S. for its ulcerative colitis drug candidate cobitolimod, according to a press release.
Cobitolimod, formerly known as DIMS0150 (Kappaproct), is a novel, locally-acting toll-like receptor 9 (TLR9) agonist that has induced remission in patients with moderate-to-severe UC who failed conventional therapy, according to results from the COLLECT study.
“This patent further strengthens and extends our intellectual property position for cobitolimod in the U.S., which is the most important pharmaceutical market in the world,” Peter Zerhouni, CEO of InDex Pharmaceuticals, said in the press release. “We are pleased that the [U.S. Patent and Trademark Office] confirms that cobitolimod is a unique and innovative asset for the treatment of refractory ulcerative colitis.”
The patent, filed in 2012, is titled “Method for prevention of colectomy (patent number 9492516),” and will enact an exclusivity period lasting through November 2032, with up to a 5-year term extension possible after market approval. It also provides additional protection for certain dose regimens.
The patent will be granted on November 15, InDex said, and the company has also filed patent applications in Europe, Japan and Canada.
Disclosures: Zerhouni is employed by InDex Pharmaceuticals.